Evidence map›Paper›PMID 37930022›Full record

ArticleBriefings in bioinformatics2023

COMO: a pipeline for multi-omics data integration in metabolic modeling and drug discovery.

Brandt Bessell, Josh Loecker, Zhongyuan Zhao, Sara Sadat Aghamiri, Sabyasachi Mohanty, Rada Amin, Tomáš Helikar, Bhanwar Lal Puniya

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. AutoRNAseq: Automated Bulk RNA-seq Analysis Pipeline.bioRxiv : the preprint server for biology · 2026
    Article
  4. Review
  5. Review
  6. Bioinformatics advances · 2025
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Brandt BessellDepartment of Biochemistry, University of Nebraska-Lincoln, NE, USA.
Josh LoeckerDepartment of Biochemistry, University of Nebraska-Lincoln, NE, USA.
Zhongyuan ZhaoDepartment of Biochemistry, University of Nebraska-Lincoln, NE, USA.
Sara Sadat AghamiriDepartment of Biochemistry, University of Nebraska-Lincoln, NE, USA.
Sabyasachi MohantyDepartment of Biochemistry, University of Nebraska-Lincoln, NE, USA.
Rada AminDepartment of Biochemistry, University of Nebraska-Lincoln, NE, USA.
Tomáš HelikarDepartment of Biochemistry, University of Nebraska-Lincoln, NE, USA.ORCID 0000-0003-3653-1906
Bhanwar Lal PuniyaDepartment of Biochemistry, University of Nebraska-Lincoln, NE, USA.ORCID 0000-0001-7528-3568

Funding

Software for collaborative construction, simulation, and analysis of mechanistic computational models of biological systemsR35GM119770 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI Tomas Helikar · 2016 to 2026
$4.4M
NIGMS NIH HHS R35 GM119770
6 · The paper itself

Abstract

Identifying potential drug targets using metabolic modeling requires integrating multiple modeling methods and heterogeneous biological datasets, which can be challenging without efficient tools. We developed Constraint-based Optimization of Metabolic Objectives (COMO), a user-friendly pipeline that integrates multi-omics data processing, context-specific metabolic model development, simulations, drug databases and disease data to aid drug discovery. COMO can be installed as a Docker Image or with Conda and includes intuitive instructions within a Jupyter Lab environment. It provides a comprehensive solution for the integration of bulk and single-cell RNA-seq, microarrays and proteomics outputs to develop context-specific metabolic models. Using public databases, open-source solutions for model construction and a streamlined approach for predicting repurposable drugs, COMO enables researchers to investigate low-cost alternatives and novel disease treatments. As a case study, we used the pipeline to construct metabolic models of B cells, which simulate and analyze them to predict metabolic drug targets for rheumatoid arthritis and systemic lupus erythematosus, respectively. COMO can be used to construct models for any cell or tissue type and identify drugs for any human disease where metabolic inhibition is relevant. The pipeline has the potential to improve the health of the global community cost-effectively by providing high-confidence targets to pursue in preclinical and clinical studies. The source code of the COMO pipeline is available at https://github.com/HelikarLab/COMO. The Docker image can be pulled at https://github.com/HelikarLab/COMO/pkgs/container/como.

Indexed as

MultiomicsProteomicsDatabases, FactualDrug DiscoveryHumansSoftwareautoimmune diseasescomputational pipelinedrug discoveryimmunometabolism

Identifiers

PMID37930022
PMCPMC10627799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.